CN110590697B - 2-噻唑甲醛-苯席夫碱的结构、制备和用途 - Google Patents
2-噻唑甲醛-苯席夫碱的结构、制备和用途 Download PDFInfo
- Publication number
- CN110590697B CN110590697B CN201910941293.6A CN201910941293A CN110590697B CN 110590697 B CN110590697 B CN 110590697B CN 201910941293 A CN201910941293 A CN 201910941293A CN 110590697 B CN110590697 B CN 110590697B
- Authority
- CN
- China
- Prior art keywords
- thiazole
- compound
- hydrazono
- phase synthesis
- synthesis method
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title abstract description 3
- 239000002262 Schiff base Substances 0.000 title description 12
- 239000013078 crystal Substances 0.000 claims abstract description 17
- 150000001875 compounds Chemical class 0.000 claims abstract description 14
- 239000000126 substance Substances 0.000 claims abstract description 8
- 238000002844 melting Methods 0.000 claims abstract description 3
- 230000008018 melting Effects 0.000 claims abstract description 3
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 claims description 14
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 12
- 239000003960 organic solvent Substances 0.000 claims description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- 238000006243 chemical reaction Methods 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- 239000000047 product Substances 0.000 claims description 8
- BTWNEJOURYOHME-UHFFFAOYSA-N 1,3-thiazol-2-ylhydrazine Chemical compound NNC1=NC=CS1 BTWNEJOURYOHME-UHFFFAOYSA-N 0.000 claims description 7
- REGDUZMWUOSCNE-UQNWOCKMSA-N C(/C1=CC=CC=C1)=N\N=C\C=1SC=CN=1 Chemical compound C(/C1=CC=CC=C1)=N\N=C\C=1SC=CN=1 REGDUZMWUOSCNE-UQNWOCKMSA-N 0.000 claims description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 7
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 claims description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 6
- 239000002994 raw material Substances 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 4
- 239000000706 filtrate Substances 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 3
- 201000010881 cervical cancer Diseases 0.000 claims description 3
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 201000001441 melanoma Diseases 0.000 claims description 3
- 238000010992 reflux Methods 0.000 claims description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 3
- 239000007791 liquid phase Substances 0.000 claims 2
- 238000010532 solid phase synthesis reaction Methods 0.000 claims 2
- 238000001308 synthesis method Methods 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 230000002194 synthesizing effect Effects 0.000 claims 1
- -1 2- ((E) -benzylidene) hydrazono Chemical group 0.000 abstract description 4
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 abstract description 2
- 230000001093 anti-cancer Effects 0.000 abstract description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract description 2
- 230000036961 partial effect Effects 0.000 abstract 1
- 150000004753 Schiff bases Chemical class 0.000 description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 238000005260 corrosion Methods 0.000 description 3
- 230000007797 corrosion Effects 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 238000000227 grinding Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 239000000376 reactant Substances 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 3
- 238000003746 solid phase reaction Methods 0.000 description 3
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000006555 catalytic reaction Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000000921 elemental analysis Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002189 fluorescence spectrum Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 238000012921 fluorescence analysis Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 230000005918 in vitro anti-tumor Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000000990 laser dye Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 229910052751 metal Chemical class 0.000 description 1
- 239000002184 metal Chemical class 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000012860 organic pigment Substances 0.000 description 1
- 150000002940 palladium Chemical class 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 238000002211 ultraviolet spectrum Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/28—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K11/00—Luminescent, e.g. electroluminescent, chemiluminescent materials
- C09K11/06—Luminescent, e.g. electroluminescent, chemiluminescent materials containing organic luminescent materials
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K2211/00—Chemical nature of organic luminescent or tenebrescent compounds
- C09K2211/10—Non-macromolecular compounds
- C09K2211/1003—Carbocyclic compounds
- C09K2211/1007—Non-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K2211/00—Chemical nature of organic luminescent or tenebrescent compounds
- C09K2211/10—Non-macromolecular compounds
- C09K2211/1018—Heterocyclic compounds
- C09K2211/1025—Heterocyclic compounds characterised by ligands
- C09K2211/1029—Heterocyclic compounds characterised by ligands containing one nitrogen atom as the heteroatom
- C09K2211/1037—Heterocyclic compounds characterised by ligands containing one nitrogen atom as the heteroatom with sulfur
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Materials Engineering (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Abstract
本发明涉及一种化合物晶体的结构、制备方法及部分性质。这种化合物外观呈黄色块状，熔点为：76‑78℃，分子式C11H9N3S,化学名为：2‑((E)‑(((E)‑亚苄基)亚肼基)甲基)噻唑；该化合物结构详见说明书，具有一定的荧光性质以及抗癌活性。
Description
技术领域
本发明涉及有机合成、光学材料和药物化学等领域，使用较简单的方法一步合成目标产物，其优点在于化合物结构的新颖性、简单易行的合成方法、较高的纯度以及产率。
背景技术
目前，随着现代科学技术的不断进步，人们对荧光的研究越来越多，对其荧光性质的研究也越来越深入。荧光物质在染料、有机颜料、光学增白剂、光氧化剂、涂料、化学及生化标记分析、太阳能捕集器、防伪标记、药物示踪及激光等领域得到了更为广泛的应用。其中有机荧光材料主要用于当今热门的技术，如荧光探针、荧光分析等，更是光学电子器件，DNA诊断、光化学传感器、激光染料、有机电致发光器件不可或缺的材料。
席夫碱主要是指含有亚胺或甲亚胺特征基团(-RC＝N-)的一类有机化合物，通常席夫碱是由胺和活性羰基缩合而成。席夫碱类化合物及其金属配合物主要在医药学、催化、分析化学、腐蚀以及光致变色领域有重要应用。在医学领域，席夫碱具有抑菌、杀菌、抗肿瘤、抗病毒的生物活性；在催化领域，席夫碱的钴、镍和钯的配合物已经作为催化剂使用；在分析化学领域，席夫碱作为良好配体，可以用来鉴别、鉴定金属离子和定量分析金属离子的含量；在腐蚀领域，某些芳香族的席夫碱经常作为铜的缓蚀剂；在光致变色领域，某些含有特征基团的席夫碱也具有独特的应用。
发明内容
本发明的内容是合成一种可用作荧光材料及抗癌药物的化合物，其化合物外观呈黄色块状晶体，熔点为：76-78℃，分子式C11H9N3S,化学名为：2-((E)-(((E)-亚苄基)亚肼基)甲基)噻唑，结构如下：
1、结构鉴定:
元素分析表明这种化合物具有的分子式为C11H9N3S，分子量215.27；元素分析结果(％)：实验结果：C,61.38，H,4.20，N,19.53，S,14.96；理论值:C,61.37，H,4.21，N,19.52，S,14.98；单晶结构分析表明，该物质晶体属于正交晶系，空间群为Pbca，
Z＝8；有关的1HNMR谱见附图1；附图2、附图3分别是该化合物的热椭球晶体结构图和晶体结构堆积图。
2、合成方法。
方法一，其特征在于：以(E)-2-(亚肼基)噻唑和苯甲醛为原料，在合适的有机溶剂中一步完成，步骤如下：
1)将(E)-2-(亚肼基)噻唑全部溶于合适的有机溶剂后，按照一定的物质的量之比加入苯甲醛，在一定温度下搅拌或研磨反应几小时即可完成。
2)过滤，待滤液自然挥发，析出的黄色块状晶体即为目标产物；若采用固相反应，则反应完毕用合适的有机溶剂重结晶即可得目标产物晶体。
方法二，其特征在于：以(E)-2-(亚肼基)噻唑和苯甲醛为原料，在合适的有机溶剂中一步完成，步骤如下：
1)将苯甲醛全部溶于合适的有机溶剂后，按照一定的物质的量之比加入(E)-2-(亚肼基)噻唑，在一定温度下搅拌或研磨反应几小时即可完成。
2)过滤，待滤液自然挥发，析出的黄色块状晶体即为目标产物；若采用固相反应，则反应完毕用合适的有机溶剂重结晶即可得目标产物晶体。
以上两种方法的区别在于反应物加料顺序不同，但反应物的摩尔比均介于1:4与4:1之间。
以上两种方法中的有机溶剂(包括反应用溶剂和重结晶用溶剂)选自：甲醇、乙醇、乙腈、二氯甲烷、氯仿、四氢呋喃、丙酮等，反应时也可以不用有机溶剂，原料之间直接反应(即固相反应)。
优选的,所述反应温度为常温或加热回流，反应方法为搅拌或研磨。
优选的，所述反应时间选自：1－10h。
本发明的有益效果是：能够以比较简单的步骤和反应物合成比较复杂的功能分子材料。
3、紫外和荧光性质
化合物在263.0nm和323.0nm附近有两个强吸收峰，紫外光谱见附图4；在375.0-425.0nm范围有很强的荧光发射峰，荧光光谱见附图5；这表明该化合物有较好的荧光性质。
4、体外抗肿瘤活性：
将处于对数期生长的A549肺癌细胞，A375人类恶性黑色素瘤细胞和HeLa宫颈癌细胞，分别用0.25％胰酶消化细胞，使其成为单细胞，用含10％胎牛血清的F12K培养液制成浓度为1.25×107个/L的单细胞悬液，将细胞接种于96孔培养板中，每孔200μL(每孔2.5×103个细胞)。将96孔细胞培养板置于CO2培养箱中，在37℃，5％CO2条件下，培养48h。
当孔内细胞长满(90％满即可)时，按实验分组加入不同剂量的本席夫碱溶液(200μL/孔)，使待测化合物的终浓度分别为12.5μM、25μM、50μM、100μM、200μM、400μM，每组设3个复孔，培养96h。
各个孔中分别加入20μL浓度为0.5g/L的MTT，继续培养4h，使MTT还原为甲瓒(Formazan)。吸出全部上清液后，每孔加入200μL的DMSO，震摇15min，使甲瓒充分溶解后，运用酶联免疫检测仪测定490nm处的吸光度(OD值)。然后按照下式进行计算：
细胞抑制率％＝(对照组OD值-实验组OD值)/对照组OD值×100％
测试结果表明，该席夫碱对A549肺癌细胞，A375人类恶性黑色素瘤细胞和HeLa宫颈癌细胞的IC50(药物的半数抑制浓度)分别为242、360、350μmol/L，表明该化合物对这三种癌细胞有微弱的抑制效果。
具体实施方式
为了更好的理解本发明内容，下面通过一个具体实施例进一步说明本发明的技术方案：
实施例1
称取0.1270g(约1mmol)(E)-2-(亚肼基)噻唑溶于50ml乙腈中，将溶液放入烧瓶内，放在恒温加热磁力搅拌器上搅拌，用移液枪吸取203微升(约2mmol)苯甲醛加入溶液中，加热回流搅拌反应2小时。溶液逐渐变为黄棕色，反应结束后，过滤，滤液静置，自然挥发；烧杯底部析出黄色块状晶体，即为目标产物，产率约为88％。
附图说明
附图1是2-((E)-(((E)-亚苄基)亚肼基)甲基)噻唑的1HNMR谱图(DMSO-D6)。
附图2是2-((E)-(((E)-亚苄基)亚肼基)甲基)噻唑的晶体结构图。
附图3是2-((E)-(((E)-亚苄基)亚肼基)甲基)噻唑的晶体结构堆积图。
附图4是2-((E)-(((E)-亚苄基)亚肼基)甲基)噻唑的紫外光谱图(10-5mol/L,CH2CL2)。
附图5是2-((E)-(((E)-亚苄基)亚肼基)甲基)噻唑的荧光光谱图(10-5mol/L,CH2CL2)。
Claims (3)
1.一种化合物，外观呈黄色块状晶体，熔点为：76-78℃，分子式C11H9N3S,化学名为：2 -（（E）-（（（E）-亚苄基）亚肼基）甲基）噻唑，结构如下：
该物质晶体属于正交晶系，空间群为Pbca，a = 10.9868(5) Å，b =9.7057(4)Å，c =20.1796(10)Å，V =2151.8432Å3，Z = 8。
2.如权利要求1中所述的化合物的合成方法，其特征在于：以（E）-2-（亚肼基）噻唑和苯甲醛为原料，可以采用液相合成或固相合成法：
1）若采用液相合成法，则将（E）-2-（亚肼基）噻唑全部溶于甲醇/乙醇/乙腈/二氯甲烷/氯仿/四氢呋喃/丙酮有机溶剂中后，按1:4至4:1物质的量之比加入苯甲醛，在常温或加热至回流温度下搅拌1－10h即可完成，然后过滤，待滤液自然挥发，析出的橙黄色块状晶体即为目标产物；
2）若采用固相合成法，则将两种反应原料按1:4至4:1物质的量之比混合后常温下研磨反应1－10h，然后用甲醇/乙醇/乙腈/二氯甲烷/氯仿/四氢呋喃/丙酮有机溶剂重结晶，可得目标产物晶体。
3.如权利要求1中所述化合物或其药物学上可接受的盐在制备治疗肿瘤药物中的应用，其特征在于：所述肿瘤为肺癌、恶性黑色素瘤或宫颈癌。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910941293.6A CN110590697B (zh) | 2019-09-30 | 2019-09-30 | 2-噻唑甲醛-苯席夫碱的结构、制备和用途 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910941293.6A CN110590697B (zh) | 2019-09-30 | 2019-09-30 | 2-噻唑甲醛-苯席夫碱的结构、制备和用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110590697A CN110590697A (zh) | 2019-12-20 |
| CN110590697B true CN110590697B (zh) | 2022-09-30 |
Family
ID=68865137
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910941293.6A Active CN110590697B (zh) | 2019-09-30 | 2019-09-30 | 2-噻唑甲醛-苯席夫碱的结构、制备和用途 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110590697B (zh) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009149598A (ja) * | 2007-11-29 | 2009-07-09 | Nippon Soda Co Ltd | アジン誘導体および農園芸用殺菌剤 |
| CN110229119A (zh) * | 2019-05-21 | 2019-09-13 | 辽宁科技大学 | 一种用于铁离子检测的苯并噻唑双希夫碱荧光分子探针的合成及使用方法 |
-
2019
- 2019-09-30 CN CN201910941293.6A patent/CN110590697B/zh active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009149598A (ja) * | 2007-11-29 | 2009-07-09 | Nippon Soda Co Ltd | アジン誘導体および農園芸用殺菌剤 |
| CN110229119A (zh) * | 2019-05-21 | 2019-09-13 | 辽宁科技大学 | 一种用于铁离子检测的苯并噻唑双希夫碱荧光分子探针的合成及使用方法 |
Non-Patent Citations (1)
| Title |
|---|
| "新型吲哚类希夫碱的合成、结构表征及抗癌活性研究";卜凡志;《中国优秀博硕士学位论文全文数据库（硕士） 工程科技I辑》;20180415(第04期);正文第1页第1-3段和第3页第3段 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110590697A (zh) | 2019-12-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107266348A (zh) | 联苯乙酮腙‑3‑吲哚甲醛西弗碱的制备、结构和用途 | |
| CN111187303A (zh) | 新型高抗肿瘤活性白叶藤碱铂(ii)配合物及其合成方法和应用 | |
| CN110606843B (zh) | 双吡啶酮腙-2-乙酰基吡嗪的结构、制备和用途 | |
| CN108164463A (zh) | 一种具有非小细胞肺癌选择性抑制作用的1,8-萘二甲酰亚胺衍生物及其合成方法和应用 | |
| CN110590765B (zh) | 2-噻唑甲醛-糠醛席夫碱的结构、制备和用途 | |
| CN107043345B (zh) | 联苯乙酮腙-吲哚啉-2,3-二酮西弗碱的制备、结构和用途 | |
| CN109912491B (zh) | 4-羟基二苯甲酮腙-靛红席夫碱的制备和用途 | |
| CN110790695B (zh) | 苯偶酰腙-n-甲基-3-吲哚甲醛的合成及用途 | |
| CN110590697B (zh) | 2-噻唑甲醛-苯席夫碱的结构、制备和用途 | |
| CN109824572B (zh) | 4-羟基二苯甲酮腙-1-甲基-3吲哚甲醛席夫碱的结构、制备和用途 | |
| CN110563667B (zh) | 2-噻唑甲醛-1-萘席夫碱的结构、制备和用途 | |
| CN110563716B (zh) | 2-噻唑甲醛-6-吲哚席夫碱的结构、制备和用途 | |
| CN110590764B (zh) | 2-噻唑甲醛-4-吡啶席夫碱的结构、制备和用途 | |
| CN110577521B (zh) | 2-噻唑甲醛-2-吡啶席夫碱的结构、制备和用途 | |
| CN107501303B (zh) | 一种布洛芬与喹啉-8-甲醛席夫碱构筑的铜(ii)配合物及其合成方法和应用 | |
| CN109824647B (zh) | 4-羟基二苯甲酮腙-2-乙酰基噻吩席夫碱的制备和用途 | |
| CN110590763B (zh) | 2-噻唑甲醛-噻吩席夫碱的结构、制备和用途 | |
| CN109912451B (zh) | 4-羟基二苯甲酮腙-水杨醛席夫碱的制备和用途 | |
| CN109824541B (zh) | (1z，2z)-1,2-双((2-氟苯基)(4-氟苯基)亚甲基)肼的制备和用途 | |
| CN110698383B (zh) | 苯偶酰腙-3-乙酰基吲哚的结构、合成及用途 | |
| CN109912517B (zh) | 4-羟基二苯甲酮腙-2-乙酰基吡嗪席夫碱的制备和用途 | |
| CN110590696B (zh) | 2-噻唑甲醛席夫碱的结构、制备和用途 | |
| CN108148080B (zh) | 金属有机金(iii)配合物及其合成方法和应用 | |
| CN107118147B (zh) | 联苯乙酮腙-3-乙酰基吲哚西弗碱的制备、结构和用途 | |
| CN105348146A (zh) | 二苯乙二酮腙-氯代苯甲醛双席夫碱的结构、制备和用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20221213 Address after: Room 3115, No. 135, Ward Avenue, Ping'an Street, Changqing District, Jinan, Shandong 250300 Patentee after: Shandong Jiqing Technology Service Co.,Ltd. Address before: 250353 Qilu University of technology, Changqing University Town, Jinan City, Shandong Province Patentee before: Qilu University of Technology |
|
| TR01 | Transfer of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Structure, preparation, and application of 2-thiazolaldehyde benzene Schiff base Effective date of registration: 20231122 Granted publication date: 20220930 Pledgee: Qilu bank Limited by Share Ltd. Ji'nan Changqing branch Pledgor: Shandong Jiqing Technology Service Co.,Ltd. Registration number: Y2023980067041 |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Granted publication date: 20220930 Pledgee: Qilu bank Limited by Share Ltd. Ji'nan Changqing branch Pledgor: Shandong Jiqing Technology Service Co.,Ltd. Registration number: Y2023980067041 |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20240717 Address after: 250353 University Road, Changqing District, Ji'nan, Shandong Province, No. 3501 Patentee after: Qilu University of Technology (Shandong Academy of Sciences) Country or region after: China Address before: 250306 Room 3115, No. 135, Ward Avenue, Ping'an Street, Changqing District, Jinan City, Shandong Province Patentee before: Shandong Jiqing Technology Service Co.,Ltd. Country or region before: China |